Glaucoma is a progressive optic neuropathy characterised by retinal ganglion cell degeneration and visual field loss. Glaucoma is considered to be the leading cause of blindness in the industrialised countries. Oxidative damage is an important pathogenic factor in glaucoma, which triggers trabecular meshwork (TM) degeneration, which then leads to intraocular hypertension. Neurodegenerative insults during glaucomatous neurodegeneration initiate an immune response to restore tissue homeostasis. However, the oxidative stress (OS) that develops during the pathogenic processes of glaucoma, along with the agerelated OS, plays a critical role in shifting the physiological equilibrium. In the TM from glaucoma donors, proinflammatory markers were found, which were induced by the activation of a stress response. Chronic changes in the composition of antioxidants found in aqueous humour may induce alterations in TM as well as in the optic nerve head cells. Highlighting the pathogenic role of reactive oxygen species (ROS) in glaucoma has implications in preventing this disease. Various clinical trials are available to test the efficacy of antioxidant drugs in glaucoma management. In this review, we discuss the OS as a therapeutic target, suggesting that the modulation of a pro-oxidant/antioxidant status might be a relevant target for glaucoma prevention and therapy.
StowellCBurgoyneCFTammER, et al.Biomechanical aspects of axonal damage in glaucoma: a brief review. Exp Eye Res2017; 157: 13–19.
2.
TezelG. Oxidative stress in glaucomatous neurodegeneration:mechanisms and consequences. Prog Retin Eye Res2006; 25: 490–513.
3.
EnginKNYemişciBYiğitU, et al.Variability of serum oxidative stress biomarkers relative to biochemical data and clinical parameters of glaucoma patients. Mol Vision2010; 16: 1260–1271.
4.
IzzottiABagnisASaccaSC. The role of oxidative stress in glaucoma. Mutat Res2006; 612: 105–114.
5.
KamelKFarrellMO’BrienC. Mitochondrial dysfunction in ocular disease: focus on glaucoma. Mitochondrion2017; 35: 44–53.
6.
AlvaradoJAAlvaradoRGYehRF, et al.A new insight into the cellular regulation of aqueous outflow: how trabecular meshwork endothelial cells drive a mechanism that regulates the permeability of Schlemm’s canal endothelial cells. Br J Ophthalmol2005; 89: 1500–1505.
7.
ChrysostomouVRezaniaFTrounceAI, et al.Oxidative stress and mitochondrial dysfunction in glaucoma. Curr Opin Pharmacol2013; 13: 12–15.
8.
FerreiraSMLernerSFBrunziniR, et al.Oxidative stress markers in aqueous humor of glaucoma patients. Am J Ophthalmol2004; 137: 62–69.
9.
SaccaSCIzzottiARossiP, et al.Glaucomatous outflow pathway and oxidative stress. Exp Eye Res2007; 84: 389–399.
10.
AslanMDoganSKucuksayanE. Oxidative stress and potential applications of free radical scavengers in glaucoma. Redox Rep2013; 18: 76–87.
11.
IorioEL. Free radicals, antioxidants and oxidative stress in aesthetic medicine and dermatology. Eur J Aesthet Med Dermatol2016; 6: 9–47.
12.
JonesDP. Redox theory of aging. Redox Biol2015; 5: 71–79.
13.
ChidlowGWoodJPMCassonRJ. Investigations into hypoxia and oxidative stress at the optic nerve head in a rat model of glaucoma. Front Neurosci2017; 11: 478.
14.
ZhaoJWangSZhongW, et al.Oxidative stress in the trabecular meshwork. Int J Mol Med2016; 38: 995–1002.
15.
LawlerTLiuYChristensenK, et al.Dietary antioxidants, macular pigment, and glaucomatous neurodegeneration: a review of the evidence. Nutrients2019; 11: 1002.
16.
FlammerJKonieczkaKFlammerAJ. The primary vascular dysregulation syndrome: implications for eye diseases. EPMA J2013; 4: 14.
17.
CaballeroMLitonPBEpsteinDL, et al.Proteasome inhibition by chronic oxidative stress in human trabecular meshwork cells. Biochem Biophys Res Commun2003; 308: 346–352.
18.
FerreiraSMLernerSFBrunziniR, et al.Oxidative stress markers in aqueous humor of glaucoma patient. Am J Ophthalmol2004; 137: 62–69.
19.
SaccaSCPascottoACamicioneP, et al.Oxidative DNA damage in the human trabecular meshwork: clinical correlation in patients with primary open-angle glaucoma. Arch Ophthalmol2005; 123: 458–463.
20.
SaccaSCIzzottiA. Focus on molecular events in the anterior chamber leading to glaucoma. Cell Mol Life Sci2014; 71: 2197–2218.
JohnsonECMorrisonJC. Friend or foe? Resolving the impact of glial responses in glaucoma. J Glaucoma2009; 18: 341–353.
23.
TezelGYangXLuoC, et al.Mechanisms of immune system activation in glaucoma: oxidative stress-stimulated antigen presentation by the retina and optic nerve head glia. Invest Ophthalmol Vis Sci2007; 48: 705–714.
24.
SchwartzMZivY. Immunity to self and self-maintenance: a unified theory of brain pathologies. Trends Immunol2008; 29: 211–219.
BirbenESahinerUMSackesenC, et al.Oxidative stress and antioxidant defense. World Allergy Organ J2012; 5: 9–19.
27.
HammamTMontgomeryDMorrisD, et al.Prevalence of serum autoantibodies and paraproteins in patients with glaucoma. Eye2008; 22: 349–353.
28.
TezelGYangXLuoC, et al.Oxidative stress and the regulation of complement activation in human glaucoma. Invest Ophthalmol Vis Sci2010; 51: 5071–5082.
29.
TezelG. The immune response in glaucoma: a perspective on the roles of oxidative stress. Exp Eye Res2011; 93: 178–186.
30.
KuehnMHKimCYOstojicJ, et al.Retinal synthesis and deposition of complement components induced by ocular hypertension. Exp Eye Res2006; 83: 620–628.
31.
TezelGYangXLuoC, et al.Mechanisms of immune system activation in glaucoma: oxidative stress-stimulated antigen presentation by the retina and optic nerve head Glia. Invest Ophthalmol Vis Sci2014; 48: 705–714. doi:10.1167/iovs.06-0810
32.
Caceres-VelezPRHuiFHercusJ, et al.Restoring the oxidative balance in age-related diseases – an approach in glaucoma (review). Ageing Res Rev2022; 75: 101572.
33.
GherghelDGriffithsHRHiltonEJ, et al.Systemic reduction in glutathione levels occurs in patients with primary open-angle glaucoma. Invest Opthalmol Vis Sci2005; 46: 877.
34.
OshidaEMatsumotoYAraiK. Free radicals in the aqueous humor of patients with glaucoma. Clin Ophthalmol2010; 4: 653–660. doi:10.2147/OPTH.S10922
35.
KalousovaMZimaTTesarV, et al.Advanced glycoxidation end products in chronic diseasesclinical chemistry and genetic background. Mutat Res2005; 579: 37–46.
36.
Zanon-MorenoVMarco-VenturaPLleo-PerezAV, et al.Oxidative stress in primary open-angle glaucoma. J Glaucoma2008; 17: 263–268.
37.
GhanemAAArafaLFEl-BazA. Oxidative stress markers in patients with primary open-angle glaucoma. Curr Eye Res2010; 35: 295–301.
38.
GartaganisSPPatsoukisNENikolopoulosDK, et al.Evidence for oxidative stress in lens epithelial cells in pseudoexfoliation syndrome. Eye2007; 21: 1406–1411.
39.
TezelGYangXCaiJ. Proteomic identification of oxidatively modified retinal proteins in a chronic pressure-induced rat model of glaucoma. Invest Ophthalmol Vis Sci2005; 46: 3177–3187.
40.
MirzaeiMGuptaVKChitranshiN, et al.Retinal proteomics of experimental glaucoma model reveal intraocular pressure-induced mediators of neurodegenerative changes. J Cell Biochem2020; 121: 4931–4944.
41.
AfonsoVChampyRMitrovicD, et al.Reactive oxygen species and superoxide dismutases: role in joint diseases. Joint Bone Spine2007; 74: 324–329.
42.
EgeaJFabregatIFrapartTM, et al.European contribution to the study of ROS: a summary of the findings and prospects for the future from the COST action BM1203 (EU-ROS). Redox Biol2017; 13: 94–162.
43.
GebickaLKrych-MadejJ. The role of catalases in the prevention/promotion of oxidative stress. J Inorg Biochem2019; 197: 110699.
44.
MajsterekIMalinowskaKStanczykM, et al.Evaluation of oxidative stress markers in pathogenesis of primary open-angle glaucoma. Exp Mol Pathol2011; 90: 231–237.
45.
IzzottiALongobardiMCartigliaC, et al.Proteome alterations in primary open angle glaucoma aqueous humor. J Proteome Res2010; 9: 4831–4838.
46.
YağciRGürelAErsözI, et al.Oxidative stress and protein oxidation in pseudoexfoliation syndrome. Curr Eye Res2006; 31: 1029–1032.
47.
BagnisAIzzottiASaccaSC. Aqueous humor oxidative stress proteomic levels in primary open angle glaucoma. Exp Eye Res2012; 103: 55–62.
48.
GuymerCWoodJPChidlowG, et al.Neuroprotection in glaucoma: recent advances and clinical translation. Clin Exp Ophthalmol2019; 47: 88–105.
49.
Garcia-MedinaJJRubio-VelazquezELopez-BernalMD, et al.Glaucoma and antioxidants: review and update. Antioxidants2020; 9: 1031.
50.
AngeloniCBusinaroRVauzourD. The role of diet in preventing and reducing cognitive decline. Curr Opin Psychiatry2020; 33: 432–438.
51.
Bernardo-ColonAVestVClarkA, et al.Antioxidants prevent inflammation and preserve the optic projection and visual function in experimental neurotrauma. Cell Death Dis2018; 9: 1097.
52.
AhmedEDonovanTYujiaoL, et al.Mitochondrial targeted antioxidant in cerebralischemia. J Neurol Neurosci2015; 6: 17.
53.
QuarantaLRivaIBiagioliE, et al.Evaluating the effects of an ophthalmic solution of coenzyme Q10 and vitamin E in open-angle glaucoma patients: a study protocol. Adv Ther2019; 36: 2506–2514.
54.
ParisiVCentofantiMGandolfiS, et al.Effects of coenzyme Q10 in conjunction with vitamin E on retinal-evoked and cortical-evoked responses in patients with open-angle glaucoma. J Glaucoma2014; 23: 391–404.
55.
BuosiFSAlaimoADi SantoMC, et al.Resveratrol encapsulation in high molecular weight chitosan-based nanogels for applications in ocular treatments: impact on human ARPE-19 culture cells. Int J Biol Macromol2020; 165: 804–821.
56.
LunaCLiGLitonPB, et al.Resveratrol prevents the expression of glaucoma markers induced by chronic oxidative stress in trabecular meshwork cells. Food Chem Toxicol2009; 47: 198–204.
57.
MayackBKSipplWNtie-KangF. Natural products as modulators of sirtuins. Molecules2020; 25: 3287. doi:10.3390/molecules25143287
58.
LuoJMillsKCessieS, et al.Ageing, age-related diseases and oxidative stress: what to do next?Ageing Res Rev2020; 57: 100982.
59.
DavisBMPahlitzschMGuoL, et al.Topical curcumin nanocarriers are neuroprotective in eye disease. Sci Rep2018; 8: 11066.
60.
MartinsNBarrosLFerreiraICFR. In vivo antioxidant activity of phenolic compounds: facts and gaps. Trends Food Sci Technol2016; 48: 1–12.
61.
Cybulska-HeinrichAKMozaffariehMFlammerJ. Ginkgo biloba: an adjuvant therapy for progressive normal and high tension glaucoma. Mol Vision2012; 18: 390–402.
62.
GuCHowellKDunsheaFR, et al.LC-ESI-QTOF/MS characterisation of phenolic acids and flavonoids in polyphenol-rich fruits and vegetables and their potential antioxidant activities. Antioxidants2019; 8: 1–15. doi:10.3390/antiox8090405
63.
ParkJWKwonHJChungWS, et al.Short-term effects of Ginkgo biloba extract on peripapillary retinal blood flow in normal tension glaucoma. Korean J Ophthalmol2011; 25: 323–328.
64.
MarreiroDDCruzKJMoraisJB, et al.Zinc and oxidative stress: current mechanisms. Antioxidants2017; 6: 24.
65.
Garcia-MedinaJJGarcia-MedinaMGarrido-FernandezP, et al.A two-year follow-up of oral antioxidant supplementation in primary open-angle glaucoma: an open-label, randomized, controlled trial. Acta Ophthalmol (Copenh)2014; 93: 546–554.
66.
KimJHanSYMinH. Ginseng for an eye: effects of ginseng on ocular diseases. J Ginseng Res2020; 44: 1–7.
67.
KimuraAGuoXNoroT, et al.Valproic acid prevents retinal degeneration in a murine model of normal tension glaucoma. Neurosci Lett2014; 588: 108–113. doi:10.1016/j.neulet.2014.12.054
68.
ZhangZQinXZhaoX, et al.Valproic acid regulates antioxidant enzymes and prevents ischemia/reperfusion injury in the rat retina. Curr Eye Res2012; 37: 429–437.
69.
OzawaYYukiKYamagishiR, et al.Renin-angiotensin system involvement in the oxidative stressinduced neurodegeneration of cultured retinal ganglion cells. Jpn J Ophthalmol2013; 57: 126–132.
70.
SembaKNamekataKGuoX, et al.Renin-Angiotensin system regulates neurodegeneration in a mouse model of normal tension glaucoma. Cell Death Dis2014; 5: 13–33.
71.
LeeKYCNakayamaMAiharaM, et al.Brimonidine is neuroprotective against glutamateinduced neurotoxicity, oxidative stress, and hypoxia in purified rat retinal ganglion cells. Mol Vision2010; 16: 246–251.
72.
YuALFuchshoferRKampikA, et al.Effects of oxidative stress in trabecular meshwork cells are reduced by prostaglandin analogues. Invest Ophthalmol Vis Sci2008; 49: 4872–4880.
73.
Line StorgaardLTranTLClement FreibergJ, et al.Glaucoma clinical research: trends in treatment strategies and drug development. Front Med (Lausanne)2021; 8: 733080.
74.
TribbleJROtmaniASunS, et al.Nicotinamide provides neuroprotection in glaucoma by protecting against mitochondrial and metabolic dysfunction. Redox Biol2021; 43: 101988.
75.
LambiaseAAloeLCentofantiM, et al.Experimental and clinical evidence of neuroprotection by nerve growth factor eye drops: implications for glaucoma. Proc Natl Acad Sci2009; 106: 13469–13474.
76.
CoskerKECourchesneSLSegalRA. Action in the axon: generation and transport of signaling endosomes. Curr Opin Neurobiol2008; 18: 270–275.
77.
BollaPKGoteVSinghM, et al.Luteinloaded, biotin-decorated polymeric nanoparticles enhance lutein uptake in retinal cells. Pharmaceutics2020; 12: 1–17. doi:10.3390/pharmaceutics12090798
78.
MietznerRKadeCFroemelF, et al.Fasudil loaded PLGA microspheres as potential intravitreal depot formulation for glaucoma therapy. Pharmaceutics2020; 12: 706.
79.
SahAKBhuwaneNChoudharyI, et al.Application of biocompatible nanocarriers in glaucoma: challenges and advances. In: Nanoformulations in human health. Cham: Springer International Publishing, 2020, pp.207–226.
